LOC728373 Inhibitors
LOC728373 Inhibitors pertains to a group of compounds that specifically target and modulate the activity of LOC728373, a gene with a yet-to-be-fully elucidated function. LOC728373, identified by its gene locus, has been the subject of scientific interest due to its potential role in various cellular processes, though the exact mechanisms and pathways it influences remain unclear. The inhibitors designed for LOC728373 act as molecular tools to selectively hinder or suppress the gene's function, allowing researchers to explore the consequences of its inhibition on cellular functions and physiological processes.
These inhibitors are meticulously designed molecules that interact with specific binding sites or active regions within the LOC728373 gene, disrupting its normal activity. The rationale behind developing such inhibitors lies in the pursuit of understanding the biological pathways influenced by LOC728373, and the potential implications for cellular homeostasis. Researchers employ these inhibitors in laboratory settings to investigate the downstream effects of LOC728373 inhibition, contributing to the broader understanding of gene function and its impact on cellular behavior. While the specific details of the inhibitors' chemical structures may vary, their common purpose is to selectively modulate LOC728373, facilitating the exploration of its role in cellular processes and advancing our knowledge of gene function at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 prevents the activation of the AKT signaling pathway. Given that LOC728373 is associated with cellular processes modulated by PI3K/AKT, inhibition of this pathway would lead to reduced phosphorylation and activation of downstream proteins, thereby decreasing the functional activity of LOC728373. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, U0126 impedes the MAPK/ERK pathway. LOC728373, which may be regulated by this pathway, would experience decreased activation as a result of diminished signal transduction through ERK1/2, thereby inhibiting LOC728373’s function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound specifically inhibits p38 MAP kinase. Inhibition of p38 MAPK can alter the stress response and cytokine production within cells. As LOC728373 might be involved in such cellular responses, SB203580 would indirectly decrease LOC728373's activity by attenuating relevant signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin leads to the deactivation of the mTORC1 complex, which is integral to cell growth and proliferation. LOC728373, potentially regulated by mTOR pathways, would have decreased functional activity due to reduced protein synthesis and cell proliferation signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As another PI3K inhibitor, Wortmannin blocks the PI3K/AKT pathway, which can reduce the activity of downstream proteins involved in cell survival and growth. This inhibition could decrease LOC728373's activity if it is downstream or regulated by the PI3K/AKT pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinase), SP600125 would suppress the JNK signaling involved in cellular stress responses. If LOC728373 is modulated by JNK signaling, its activity would be indirectly decreased by this inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound inhibits MEK, which is upstream of ERK in the MAPK pathway. By blocking MEK activation, PD98059 would reduce ERK-mediated signaling, potentially leading to decreased activity of LOC728373 if it is influenced by the MAPK pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor, Imatinib specifically targets BCR-ABL, c-KIT, and PDGFR. If LOC728373 is involved in pathways or cellular processes associated with these kinases, its activity would be indirectly inhibited by Imatinib. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, Bortezomib disrupts the degradation of proteins regulated by the ubiquitin-proteasome system. If LOC728373's function is linked to proteins that are normally degraded by the proteasome, its activity could be indirectly inhibited due to altered protein turnover. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
As an EGFR inhibitor, Gefitinib would block the signaling pathways downstream of EGFR, which could include the regulation of LOC728373. By inhibiting EGFR, the functional activity of LOC728373 may be reduced if it is involved in the EGFR signaling pathway. | ||||||